VANCOUVER, BC / ACCESSWIRE / June 27, 2016 / iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) (“iCo” or “the Company”), today announced that all nominees listed in the management information circular dated May 30, 2016 were elected as directors at its 2016 Annual Meeting of Shareholders, held on June 24 2016. On a vote by ballot, the following 4 nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:

Please refer to the Company’s management information circular available on SEDAR at www.sedar.com for more details on the matters covered at the annual meeting. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

About iCo Therapeutics

iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company holds worldwide rights to an oral drug delivery platform, with Oral Amphotericin B (Amp B) as the initial platform candidate, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. iCo also has worldwide rights to two drug candidates: iCo-007 is a second generation antisense drug candidate targeting C-Raf kinase and iCo-008 is a monoclonal antibody targeting eotaxin-1. With Phase 2 clinical history, Bertilimumab (iCo-008) is a candidate for the treatment of vernal or atopic keratoconjunctivitis and wet age-related macular degeneration. iCo-008 is in Phase 2 clinical studies with iCo’s partner, Immune Pharmaceuticals. iCo trades on the TSX Venture Exchange under the symbol “ICO” and the OTCQX under the symbol “ICOTF”. For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Mr. John Meekison, CFO
iCo Therapeutics
604-602-9414 x 224
meekison@icotherapeutics.com

Andrew Rae, CEO
iCo Therapeutics
778-772-7775
rae@icotherapeutics.com

SOURCE: iCo Therapeutics

ReleaseID: 441703

NEW YORK, NY / ACCESSWIRE / June 27, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Suffolk Bancorp (NYSE: SCNB) stock prior to June 27, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Suffolk Bancorp to People’s United Financial, Inc. (NASDAQ: PBCT). Under the terms of the transaction, Suffolk Bancorp shareholders will receive 2.225 shares of People’s United Financial stock for each Suffolk Bancorp share they own. Based on the closing price of People’s United stock prior to the merger announcement, this represents a value of approximately $33.55 per share. To learn more about the action and your rights, go to:

http://zlk.9nl.com/suffolk-bancorp-scnb

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 441702

TORONTO, ON / ACCESSWIRE / June 27, 2016 / Cava Resources Inc. (TSXV: CVA) (“Cava” or, the “Company”) announces that the Company intends to close a private placement financing of up to 15,000,000 units at an issue price of $0.05 per unit for gross proceeds of up to $750,000. Each unit will be comprised of one common share and one common share purchase warrant, with each warrant exercisable into a common share at an exercise price of $0.15 per share for a period of 24 months.

Proceeds from the financing will be used to advance the Company’s Casa Berardi property and for general corporate purposes.

For further information contact:

R. Brian Murray
President, 416-985-7810

John V. Hickey
CFO, 416-903-6649

The TSXV has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release. The TSXV has neither approved nor disapproved the contents of this news release.

All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding potential mineralization and reserves, exploration results, and future plans and objectives of the Company, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are exploration risks detailed herein and from time to time in the filings made by the Company with securities regulators.

SOURCE: Cava Resources Inc.

ReleaseID: 441700

VANCOUVER, BC / ACCESSWIRE / June 27, 2016 / Ecuador Gold & Copper Corp. (TSXV: EGX) (the “Company“), wishes to announce that further to its news release dated June 10, 2016, it is increasing its new debenture offering (the “Debenture Offering“) from the previously announced US$900,000 to raise aggregate gross proceeds now of up to US$1,250,000 through the issuance of senior secured convertible debentures and other unsecured convertible debentures (collectively, the “Debentures“).

Each Debenture shall bear interest of 12% per annum with the principal amount and interest due and payable on December 31, 2016 (the “Maturity Date“) unless converted into units (the “Units“) of the Company at a price of C$0.40 per Unit by the Maturity Date. Each Unit will be comprised of one common share and one-half common share purchase warrant (each whole warrant a “Warrant“) of the Company. Each Warrant entitles the investor to acquire one additional common share of the Company at an exercise price of C$0.40 per share for 24 months following the date of issuance.

The proceeds of the Debenture Offering will be used for the Company’s Condor Gold Project, in-country working capital in Ecuador, and as additional working capital of the Company. The Debenture Offering is subject to approval of the TSX Venture Exchange and all securities issued under the Debenture Offering will be subject to a statutory four-month hold period from the date of issuance. No finders fees will be paid in connection with the Debenture Offering.

About Ecuador Gold and Copper Corp.

Ecuador Gold and Copper Corp. is a Canadian exploration and mining company focused on its gold and copper mineral properties located in the Province of Zamora-Chinchipe in southern Ecuador. The Company has completed a Preliminary Economic Assessment of its Santa Barbara Gold and Copper Project dated May 29, 2015, and is currently listed on the TSX Venture Exchange under the symbol “EGX”. For additional information, please visit us at www.ecuadorgoldandcopper.com.

For further information please contact:

Heye Daun
President, Chief Executive Officer and Director
Telephone: +1-604-687 2038 (Vancouver Office)
Email: hdaun@ecuadorgoldandcopper.com

Cautionary Note

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

SOURCE: Ecuador Gold & Copper Corp.

ReleaseID: 441699

IRVINE, CA / ACCESSWIRE / June 27, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Vivint Solar, Inc. (“Vivint” or the “Company”) (NYSE: VSLR). Investors who purchased or otherwise acquired shares between July 20, 2015 and March 7, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 5, 2016, lead plaintiff motion deadline.

If you purchased shares of Vivint during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company failed to disclose that (1) SunEdison would be unable to obtain financing for the acquisition of Vivint; (2) SunEdison’s liquidity was less than Defendants had stated; and (3) SunEdison would not be able to complete the acquisition of Vivint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 441698

LOS ANGELES, CA / ACCESSWIRE / June 27, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Intrexon Corporation (“Intrexon” or the “Company”) (NYSE: XON) concerning possible violations of federal securities laws between May 12, 2015 and April 20, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 5, 2016, lead plaintiff motion deadline.

For more information or to participate, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) Intrexon was overstating its revenue; and (2) as a result, Defendants’ statements about Intrexon’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com

SOURCE: Lundin Law PC

ReleaseID: 441697

IRVINE, CA / ACCESSWIRE / June 27, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Sunrun Inc. (“Sunrun” or the “Company”) (Nasdaq: RUN). Investors who purchased or otherwise acquired shares traceable to the Company’s Initial Public Offering (the “IPO”) on August 5, 2015, have until July 5, 2016, to move as lead plaintiff.

If you purchased shares of Sunrun during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company failed to disclose that: (1) Sunrun’s actual historical operating costs were being understated by not identifying and disclosing the fixed grid costs being borne for it by public utilities where net metering programs were being employed; and (2) Sunrun had been charging well above wholesale rates for the electricity it was selling to its net metering customers.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 441696

• Double digit growth in revenue and adjusted EBITDA the result of accelerated sales and marketing efforts both domestically and international
• Hosting first International Distributor Meeting in Europe
• Continued gross margin expansion as lean initiatives come to fruition
• Thanks Cyril Narishkin for his service as President, Interim COO and Board Director

CHESTER, NY / ACCESSWIRE / June 27, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced its financial results for the first quarter of the fiscal year ending February 28, 2017.

For the quarter ended May 31st, net revenues increased $360 thousand, or 13.7%, compared to the previous year’s Q1, led by the Company’s sales of proprietary infusion products. Net revenues for the first quarter of fiscal 2017 were $2,990,166 compared with $2,630,545 in the comparable quarter.

RMS is benefiting from recent lean manufacturing initiatives to streamline operations, which have resulted in increased capacity and decreased direct assembly labor costs, as well as the moratorium on the medical device tax. Gross profit increased 27.6% to $1,936,812, up more than $400 thousand from $1,517,859 in the comparable quarter. Gross profit margin as a percentage of net sales increased to 64.8% from 57.7% in the first quarter of 2016. Non-GAAP EBITDA increased to over $330 thousand, up from a non-GAAP EBITDA loss of $33 thousand from the comparable quarter.

As a result of consulting and professional fees related to regulatory and litigation in the quarter, the Company reported a net loss of $233,314, an increased loss compared to a loss of $64,640 in the same period last year. Excluding consulting and professional fees related to regulatory and litigation (summarized in attached tables), net income would have been $174,853 in the quarter.

In addition, effective June 24, 2016, Cyril N. Narishkin has resigned from his positions of President, Interim Chief Operating Officer and Director due to personal reasons.

“By remodeling operations, and capitalizing on growth opportunities both domestically and internationally, RMS is continuing its upward trend this year,” noted Andy Sealfon, CEO of the Company. “I’d like to thank Cyril Narishkin for his service and support over the last year. We wish him continued success going forward.” Mr. Sealfon added.

In addition to participating in several industry conferences/exhibitions over the past 6 months, RMS is excited to have hosted an International Distributor Meeting. The meeting, held in Europe, provided a forum and network for representatives from European countries to speak face-to-face about the infusion market as it stands now, developments on the horizon and positioning of RMS products within those markets. “By actively listening to distributor feedback and selectively investing in new innovations for delivery systems, I am confident that RMS will continue to be a leader in the industry,” commented Mr. Sealfon.

This press release includes non-GAAP financial measures that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.

Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. A reconciliation of our non-GAAP measures is included in an attachment to this press release.

The Company manufactures medical products used for infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge™ Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company’s RES-Q-VAC line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The Company’s website may be visited at www.rmsmedicalproducts.com.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission.

For more information please call:

Mike King
702 650 3000
Princeton Research

SOURCE: Repro Med Systems, Inc.

ReleaseID: 441695

Interim President to Expand Business Operations into Audio & Entertainment Industry

SALT LAKE CITY, UT / ACCESSWIRE / June 27, 2016 / Compass Biotechnologies Inc. (OTCPK: COBI), a cutting edge audio and entertainment company, officially confirms that Mr. Steven Smith has been named interim President and principal officer of the company. Mr. Smith has served as Compass’s interim President since March of 2016.

Mr. Smith’s experience ranges from being a musician, DJ, studio engineer, and music producer, to traditional audio equipment, digital audio programming and live event production. As President, Mr. Smith intends to continue utilizing his expertise and relationships to acquire, develop and expand audio and music related equipment business development channels for the company. In addition, the company is evaluating the creation and/or acquisition of a music / concert / artist-related / live event entertainment company to further expand on the previously announced targeted acquisition of the Motion Sound product line.

In line with Mr. Smith’s vision for the company, an application will be filed for a name and ticker change to better encompass the company’s current and future business operations.

“This is an extremely exciting time for myself and the Company. The several months of hard work and preparation which have been dedicated to this new business direction now afford the opportunity to launch our audio and entertainment divisions,” said President Smith. “A new corporate name and ticker symbol will mark the beginning of the Company’s new vision and commitment to deliver ongoing shareholder value. We will strive to be transparent and communicate regularly with our consumers, clients and shareholders through many different media outlets and
social media channels. We have set the bar high, and our team looks forward to the challenges and opportunities ahead of us.”

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations and assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Some of these uncertainties include, without limitation, the company’s ability to perform under existing contracts or to procure future contracts. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, successful implementation of our business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward-looking statements.

Investor Relations 

info@compasscobi.com
https://twitter.com/compasscobi

SOURCE: Compass Biotechnologies Inc.

ReleaseID: 441694

NEW YORK, NY / ACCESSWIRE / June 27, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Daimler AG (“Daimler” or “the Company”) (OTC: DDAIF, DDAIY). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Daimler ADRs between February 22, 2012 through April 21, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that throughout the Class Period defendants issued false and misleading statements about Daimler’s compliance with emissions standards and Daimler’s purported eco-friendly BlueTEC diesel engines. On April 21, 2016, Daimler said that it is investigating at the request of the US Department of Justice “possible indications of irregularities” about its certification process of exhaust emissions in the United States. Following this news, DDAIF stock dropped $3.63 per share or over 5% to close at $70.85 per share and DDAIY stock dropped $3.83 per share or over 5% to close at $70.76 per share on April 22, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, you can visit the firm’s website: http://www.bgandg.com/#!daimler/to58x. To discuss this action, or if you have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Daimler you have until June
28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441688